LURBINECTEDIN en Combinación con PEMBROLIZUMAB Para SCLC . El Ensayo Clínico LUPER DE FASE I-II Con 28 Pacientes Podría Concluir a Principios 2024 ... De Salir Bien Lógicamente Empezarán a Preparar la Definitiva Fase III Que Podría Empezar a Finales 2024 ... y Concluir entre Finales 2027 Inicios 2028 .

Study Type  :	Interventional  (Clinical Trial)
Estimated Enrollment  :	28 participants
Allocation:	N/A
Intervention Model:	Single Group Assignment
Intervention Model Description:	Phase I/II, Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin (PM01183) in Combination with Pembrolizumab in Patients with Relapsed Small Cell Lung Cancer
Masking:	None (Open Label)
Primary Purpose:	Treatment
Official Title:	Phase I/II, Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin (PM01183) in Combination With Pembrolizumab in Patients With Relapsed Small Cell Lung Cancer
Actual Study Start Date  :	September 21, 2020
Estimated Primary Completion Date  :	October 31, 2023
Estimated Study Completion Date  :	January 31, 2024